TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.96 CNY | -1.49% |
|
-0.09% | +3.89% |
| Apr. 30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
| Apr. 30 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Recommends Dividend | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With a 2024 P/E ratio at 22.95 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.89% | 3.16B | C | ||
| +43.33% | 6.3B | B- | ||
| -16.78% | 4.44B | C+ | ||
| -6.93% | 3.27B | B- | ||
| -0.88% | 2.58B | - | D+ | |
| +46.64% | 1.96B | - | ||
| -5.34% | 1.73B | - | - | |
| +1.60% | 1.68B | - | - | |
| -7.31% | 1.63B | C- | ||
| +47.94% | 1.53B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600329 Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited